Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy
出版年份 2023 全文链接
标题
Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy
作者
关键词
-
出版物
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume -, Issue -, Pages 189008
出版商
Elsevier BV
发表日期
2023-11-01
DOI
10.1016/j.bbcan.2023.189008
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- New Insights into the Understanding of Mechanisms of Radiation-Induced Heart Disease
- (2023) Kai-Xuan Wang et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
- (2023) Christine Son et al. Frontiers in Oncology
- Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis
- (2023) Xin Zhang et al. Frontiers in Cardiovascular Medicine
- Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment
- (2023) Nikhil Yegya-Raman et al. Current Oncology Reports
- Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
- (2023) Bo Yan et al. Cancer Immunology Research
- Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis
- (2023) Jing Wu et al. Frontiers in Immunology
- Oncostatin M/Oncostatin M Receptor Signal Induces Radiation-Induced Heart Fibrosis by Regulating SMAD4 in Fibroblast
- (2023) Peng Xu et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial
- (2023) Joe Y Chang et al. LANCET
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2022) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
- (2022) Qing Zhou et al. LANCET ONCOLOGY
- Comparison of stereotactic body radiotherapy and radiofrequency ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis
- (2022) Ran Zhang et al. Annals of Translational Medicine
- Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer
- (2022) Salma K. Jabbour et al. Clinical Lung Cancer
- PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model
- (2022) Yanxin Chen et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
- (2022) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
- (2022) Tsuyoshi Isawa et al. ONCOLOGIST
- Tumor‐associated macrophages regulate the function of cytotoxic T lymphocyte through PD ‐1/ PD‐L1 pathway in multiple myeloma
- (2022) Jiangbo Zhang et al. Cancer Medicine
- Protective Effect of Crocin on Immune Checkpoint Inhibitors-Related Myocarditis Through Inhibiting NLRP3 Mediated Pyroptosis in Cardiomyocytes via NF-κB Pathway
- (2022) Hui Zhang et al. Journal of Inflammation Research
- The Role of Cardioprotection in Cancer Therapy Cardiotoxicity
- (2022) Torbjørn Omland et al. JACC: CardioOncology
- Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
- (2022) F. Cortiula et al. ANNALS OF ONCOLOGY
- Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
- (2022) Dorien Laenens et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
- (2022) Marina C. Garassino et al. Journal of Thoracic Oncology
- Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data
- (2022) Yanna Lei et al. Frontiers in Pharmacology
- Cardiovascular complications of immune checkpoint inhibitors for cancer
- (2022) Franck Thuny et al. EUROPEAN HEART JOURNAL
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
- (2022) Alexander R Lyon et al. EUROPEAN HEART JOURNAL
- Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study
- (2022) Nicolas Girard et al. Journal of Thoracic Oncology
- Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
- (2022) Alice Tison et al. Nature Reviews Rheumatology
- Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis
- (2022) Yaohua Zhang et al. Science Translational Medicine
- Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy
- (2022) Charlotte Lee et al. JACC: CardioOncology
- Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems
- (2021) Rulan Ma et al. BMC CANCER
- Programmed Death-Ligand 2 Deficiency Exacerbates Experimental Autoimmune Myocarditis in Mice
- (2021) Siqi Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mean Heart Dose is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiotherapy
- (2021) Katelyn M. Atkins et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Association of Breast Cancer Irradiation With Cardiac Toxic Effects
- (2021) Icro Meattini et al. JAMA Oncology
- 63MO Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID)
- (2021) A. Hallqvist et al. Journal of Thoracic Oncology
- Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
- (2021) Nasser K Altorki et al. LANCET ONCOLOGY
- CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer
- (2021) Dirk De Ruysscher et al. Clinical Lung Cancer
- Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis
- (2021) Nestor Rubio‐Infante et al. EUROPEAN JOURNAL OF HEART FAILURE
- Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial
- (2021) Ting Xu et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents
- (2021) Vijay U. Rao et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer
- (2021) Salma K. Jabbour et al. JAMA Oncology
- Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation
- (2021) Daniel Finke et al. Cancers
- Cardiovascular Manifestations From Therapeutic Radiation
- (2021) Joshua D. Mitchell et al. JACC: CardioOncology
- Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification
- (2021) Carmen Bergom et al. JACC: CardioOncology
- Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis
- (2021) John R. Power et al. CIRCULATION
- Radiation‑induced dysfunction of energy metabolism in the heart results in the fibrosis of cardiac tissues
- (2021) Peng Xu et al. Molecular Medicine Reports
- Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
- (2021) Zhen Wang et al. Translational Lung Cancer Research
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
- (2020) G. Curigliano et al. ANNALS OF ONCOLOGY
- Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry
- (2020) José López-Sendón et al. EUROPEAN HEART JOURNAL
- Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis
- (2020) Lili Zhang et al. EUROPEAN HEART JOURNAL
- Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity
- (2020) James Lambert et al. HEART
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- (2020) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- BRCA1 protects cardiac microvascular endothelial cells against irradiation by regulating p21-mediated cell cycle arrest
- (2020) Zhi-min Zeng et al. LIFE SCIENCES
- Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
- (2020) Charles Dolladille et al. Journal for ImmunoTherapy of Cancer
- Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society
- (2020) Alexander R. Lyon et al. EUROPEAN JOURNAL OF HEART FAILURE
- Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice
- (2020) Kenjiro Tsuruoka et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects.
- (2020) Joe Y. Chang et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer.
- (2020) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
- (2020) Joerg Herrmann Nature Reviews Cardiology
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
- (2020) Charles Dolladille et al. JAMA Oncology
- Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors
- (2020) Ohad Oren et al. AMERICAN JOURNAL OF CARDIOLOGY
- A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier cancer research network LUN 14‐179
- (2020) Greg A. Durm et al. CANCER
- The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association ( HFA ), the European Association of Cardiovascular Imaging ( EACVI ) and the Cardio‐Oncology Council of the European Society of Cardiology ( ESC )
- (2020) Jelena Čelutkienė et al. EUROPEAN JOURNAL OF HEART FAILURE
- Novel Methodology to Investigate the Effect of Radiation Dose to Heart Substructures on Overall Survival
- (2020) Alan McWilliam et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling
- (2020) Wenzheng Xia et al. Cell Death & Disease
- Antigen Cross-Presentation by Macrophages
- (2020) Elke M. Muntjewerff et al. Frontiers in Immunology
- The cancer patient and cardiology
- (2020) José Luis Zamorano et al. EUROPEAN JOURNAL OF HEART FAILURE
- Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology
- (2020) Radek Pudil et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
- (2020) Joachim Alexandre et al. Journal of the American Heart Association
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
- (2020) Willemijn S M E Theelen et al. Lancet Respiratory Medicine
- Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
- (2020) James Welsh et al. Journal for ImmunoTherapy of Cancer
- Metabolic dysfunction and inflammatory disease: the role of stromal fibroblasts
- (2020) Hussein Farah et al. FEBS Journal
- Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non–Small Cell Lung Cancer
- (2020) Katelyn M. Atkins et al. JAMA Oncology
- Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
- (2020) Jennifer Cautela et al. Journal for ImmunoTherapy of Cancer
- Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study
- (2020) Roberta Noseda et al. Cancers
- The Cytokine Expression in Patients with Cardiac Complication after Immune Checkpoint Inhibitor Therapy
- (2020) Toshihiro Tsuruda et al. INTERNAL MEDICINE
- Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy
- (2020) Paaladinesh Thavendiranathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)
- (2020) Solange Peters et al. Journal of Thoracic Oncology
- Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions
- (2020) Kathryn Banfill et al. Journal of Thoracic Oncology
- Radiotherapy toxicity
- (2019) Dirk De Ruysscher et al. Nature Reviews Disease Primers
- Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study)
- (2019) Sophie Jacob et al. Radiation Oncology
- Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial
- (2019) David Ball et al. LANCET ONCOLOGY
- Cardiovascular toxicities associated with immune checkpoint inhibitors
- (2019) Jiun-Ruey Hu et al. CARDIOVASCULAR RESEARCH
- Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy
- (2019) Mengqian Li et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors
- (2019) changhua ji et al. CLINICAL CANCER RESEARCH
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
- (2019) Yucai Wang et al. JAMA Oncology
- Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
- (2019) Khashayar Esfahani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
- (2019) Joe-Elie Salem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms
- (2019) Samantha N. Champion et al. MODERN PATHOLOGY
- Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity
- (2019) Evangelos K. Oikonomou et al. JAMA Cardiology
- Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta‐analysis
- (2019) Lars Michel et al. EUROPEAN JOURNAL OF HEART FAILURE
- Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC
- (2019) Steven H. Lin et al. Journal of Thoracic Oncology
- Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer
- (2018) Marcin Skrzypski et al. CANCER TREATMENT REVIEWS
- Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer
- (2018) Neal S. McCall et al. CLINICAL CANCER RESEARCH
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- (2018) Syed S. Mahmood et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes
- (2018) Shisuo Du et al. Journal of Thoracic Oncology
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitor‐Associated Myocarditis
- (2018) Sarju Ganatra et al. ONCOLOGIST
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitors and cardiovascular toxicity
- (2018) Alexander R Lyon et al. LANCET ONCOLOGY
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient
- (2018) Juan Carlos Plana et al. JACC-Cardiovascular Imaging
- Cardiovascular Magnetic Resonance in the Oncology Patient
- (2018) Jennifer H. Jordan et al. JACC-Cardiovascular Imaging
- Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
- (2018) Y. Kanjanapan et al. EUROPEAN JOURNAL OF CANCER
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
- (2018) Joe-Elie Salem et al. LANCET ONCOLOGY
- Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials
- (2017) Carolyn Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non–Small-Cell Lung Cancer
- (2017) Robert T. Dess et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy
- (2017) Kyle Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
- (2017) Saro H. Armenian et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung
- (2017) Zhigang Yuan et al. Journal of Thoracic Oncology
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells
- (2017) Hiroaki Shime et al. OncoImmunology
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation
- (2016) Susan L. Tucker et al. RADIOTHERAPY AND ONCOLOGY
- Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
- (2016) Bridgette A. Kanz et al. Journal for ImmunoTherapy of Cancer
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
- (2015) D. Cardinale et al. CIRCULATION
- The inflammasome accelerates radiation-induced lung inflammation and fibrosis in mice
- (2015) Sung-Hwa Sohn et al. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
- (2015) Jeffrey D Bradley et al. LANCET ONCOLOGY
- Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
- (2015) Joe Y Chang et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Premature aging induced by radiation exhibits pro-atherosclerotic effects mediated by epigenetic activation of CD44 expression
- (2014) Donna Lowe et al. AGING CELL
- Cardiac Mitochondria and Reactive Oxygen Species Generation
- (2014) Yeong-Renn Chen et al. CIRCULATION RESEARCH
- Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)
- (2014) Evandro de Azambuja et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice
- (2014) J. A. Lucas et al. JOURNAL OF IMMUNOLOGY
- The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis
- (2014) C J Taylor et al. BMJ Open
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
- (2014) A. B. Sharabi et al. Cancer Immunology Research
- Understanding Radiation-induced Cardiovascular Damage and Strategies for Intervention
- (2013) F.A. Stewart et al. CLINICAL ONCOLOGY
- Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
- (2013) Sarah C. Darby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint
- (2012) Tohru Yamamori et al. FREE RADICAL BIOLOGY AND MEDICINE
- Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2012) Edward H. Romond et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of fibrosis: therapeutic translation for fibrotic disease
- (2012) Thomas A Wynn et al. NATURE MEDICINE
- Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and Inflammation
- (2011) De-xiu Bu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cardiovascular disease associated with radiotherapy: activation of nuclear factor kappa-B
- (2011) M. Halle et al. JOURNAL OF INTERNAL MEDICINE
- PD-1 deficiency results in the development of fatal myocarditis in MRL mice
- (2010) Jian Wang et al. INTERNATIONAL IMMUNOLOGY
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
- (2010) Anne Aupérin et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathogenetic mechanisms in radiation fibrosis
- (2010) John Yarnold et al. RADIOTHERAPY AND ONCOLOGY
- The Utility of Cardiovascular Magnetic Resonance in Constrictive Pericardial Disease
- (2009) Vignendra Ariyarajah et al. Cardiology in Review
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started